Establishment Labs Announces First U.S. Commercial Procedure With Motiva Flora Tissue Expander
Portfolio Pulse from Benzinga Newsdesk
Establishment Labs Holdings Inc. (NASDAQ:ESTA) announced the first U.S. commercial use of its Motiva Flora Tissue Expander at the University of Texas MD Anderson Cancer Center. The device, which recently received FDA clearance, features proprietary SmoothSilk surface technology and an RFID-enabled, non-magnetic port, making it MR conditional and reducing interference during radiation therapy. This marks a significant milestone for the company as it enters the U.S. market, the largest for breast reconstruction.
January 02, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Establishment Labs' Motiva Flora Tissue Expander was used for the first time in the U.S. following FDA clearance, signifying the company's entry into the U.S. breast reconstruction market with its innovative technology.
The first commercial use of Motiva Flora Tissue Expander in the U.S. is a positive development for Establishment Labs, indicating potential growth in the U.S. market. The FDA clearance and the unique features of the product, such as the SmoothSilk surface and non-magnetic port, could differentiate it from competitors and drive demand. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100